Angiogenic dysfunction in bone marrow-derived early outgrowth cells from diabetic animals is attenuated by SIRT1 activation

Stem Cells Translational Medicine

Volumn 1, Issue 12, 2012, Pages 921-926

  Yuen, Darren A ^a   Zhang, Yanling ^a   Thai, Kerri ^a   Spring, Christopher ^a   Chan, Lauren ^a   Guo, Xiaoxin ^b   Advani, Andrew ^a   Sivak, Jeremy M ^b   Gilbert, Richard E ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Angiogenesis; Chemokine; Diabetes; Early outgrowth cell; SIRT1

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; CXCL1 CHEMOKINE; CXCL3 CHEMOKINE; CYTOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; MESSENGER RNA; SIRTUIN 1; VASCULOTROPIN RECEPTOR 2; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR2; SIRT1 PROTEIN, RAT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOTTING; BONE MARROW CELL; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DIABETES MELLITUS; EARLY OUTGROWTH CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIFE EXTENSION; MALE; MOUSE; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DIABETIC ANGIOPATHY; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; FISCHER 344 RAT; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; MICROCIRCULATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM;

ANIMALS; BIOLOGICAL MARKERS; BONE MARROW CELLS; CELLS, CULTURED; CORNEAL NEOVASCULARIZATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HEMATOPOIETIC STEM CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, INBRED F344; RECEPTORS, INTERLEUKIN-8B; SIRTUIN 1;

MLCS; MLOWN;

EID: 84872935072     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0026     Document Type: Article

References (17)

1. Loomans CJ, de Koning EJ, Staal FJ et al. Endothelial progenitor cell dysfunction: A novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004;53:195-199.
2. Segal MS, Shah R, Afzal A et al. Nitric oxide cytoskeletal-induced alterations reverse the endothelial progenitor cell migratory defect associated with diabetes. Diabetes 2006;55:102-109.
3. Fadini GP, Miorin M, Facco M et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005;45: 1449-1457.
4. Potente M, Ghaeni L, Baldessari D et al. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev 2007; 21:2644-2658.
5. Yuen DA, Connelly KA, Advani A et al. Culture- modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism. PLoS One 2010;5:e9543.
6. Skog J, Wurdinger T, van Rijn S et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10:1470-1476.
7. Rogers MS, Birsner AE, D'Amato RJ. The mouse cornea micropocket angiogenesis assay. Nat Protoc 2007;2:2545-2550.
8. Hur J, Yoon CH, Kim HS et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004;24:288-293.
9. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008;28:1584-1595.
10. Zhang Y, Yuen DA, Advani A et al. Earlyoutgrowth bone marrow cells attenuate renal injury and dysfunction via an antioxidant effect in a mouse model of type 2 diabetes. Diabetes 2012;61:2114-2125.
11. Urbich C, Aicher A, Heeschen C et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005;39:733-742.
12. Rosenzweig A. Cardiac cell therapy: Mixed results from mixed cells. N Engl J Med 2006;355:1274-1277.
13. Zemani F, Silvestre JS, Fauvel-Lafeve F et al. Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol 2008;28:644-650.
14. Di Santo S, Yang Z, Wyler von BallmoosM et al. Novel cell-free strategy for therapeutic angiogenesis: In vitro generated conditioned medium can replace progenitor cell transplantation. PLoS One 2009;4:e5643.
15. Gurtner GC, Chang E. "Priming" endothelial progenitor cells: A new strategy to improve cell based therapeutics. Arterioscler Thromb Vasc Biol 2008;28:1034-1035.
16. Zhou S, Chen HZ, Wan YZ et al. Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction. Circ Res 2011;109:639-648.
17. Keeley EC, Mehrad B, Strieter RM. Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol 2008;28:1928-1936.